Lv6
1910 积分 2024-12-24 加入
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
10天前
已完结
Retatrutide: a triple incretin receptor agonist for obesity management
10天前
已完结
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
10天前
已完结
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
10天前
已完结
Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors
1个月前
已完结
679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
3个月前
已关闭
679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
3个月前
已关闭
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
3个月前
已完结
Triple G Agonists — A Home Run for Obesity?
3个月前
已完结
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide
3个月前
已完结
皖公网安备34019202002308
